MindMaze Therapeutics Launches Following Merger with NeuroX
MindMaze Therapeutics Holding SA has officially completed its business combination with NeuroX Group SA, creating a new entity aimed at revolutionizing care for neurological diseases. The merger, finalized on December 15, 2025, establishes MindMaze Therapeutics as a leader in delivering precision digital treatments, combining innovative technology, pharmacological solutions, and an advanced AI platform.
The completion of this transaction follows a definitive agreement signed in October 2025 and subsequent shareholder approval during an extraordinary general meeting in November. Under the new name, the company is set to operate with a unique ecosystem that integrates digital neurotherapeutics and devices, addressing a critical gap in effective care for patients suffering from neurological conditions.
Dr. Olaf Blanke, a member of the Board of Directors and Professor of Neuroscience at the Swiss Federal Institute of Technology (EPFL), emphasized the urgency of addressing neurological diseases, which currently affect one in six people globally. He noted that traditional healthcare systems often leave patients without adequate treatment options, particularly in neuro-rehabilitation. “MindMaze Therapeutics seeks to fill this gap by providing clinically validated solutions that support recovery from the hospital to home,” he stated.
Chairman of the Board, Walid Hanna, remarked on the significance of the merger, stating, “Today begins a new chapter for MindMaze Therapeutics.” He highlighted the company’s commitment to transforming neurological care and expanding its capabilities through the integration of Relief’s biopharmaceutical assets. The merger is expected to enhance the development of innovative drug-digital integration strategies.
In this transaction, MindMaze Therapeutics acquired NeuroX through a share exchange, with former NeuroX shareholders contributing all outstanding shares in return for 140,000,000 newly issued ordinary shares of MindMaze. These shares will begin trading on the SIX Swiss Exchange under the ticker symbol MMTX. Following the merger, the total number of outstanding shares has increased to 152,602,044, excluding treasury shares.
About MindMaze Therapeutics
MindMaze Therapeutics is headquartered in Geneva, Switzerland, and focuses on developing digital treatments for neurological diseases and brain disorders. The company has established a platform that integrates software, sensors, and telehealth, making its solutions available across various clinical and home settings globally. Its clinically validated neurotherapeutics have shown significant outcomes in conditions such as stroke and Parkinson’s disease.
The company also manages Relief’s portfolio of clinical and commercial biopharmaceutical assets, which target rare dermatological, metabolic, and respiratory diseases. As it moves forward, MindMaze Therapeutics aims to expand its research and development pipeline into other neurological conditions, including multiple sclerosis, traumatic brain injury, and Alzheimer’s disease.
For further information on MindMaze Therapeutics, visit their official website at www.mindmazetherapeutics.com.
This announcement contains forward-looking statements based on current plans and assumptions, which are subject to various risks and uncertainties. These factors may lead to significant differences between actual results and those anticipated. MindMaze Therapeutics does not undertake any obligation to update these statements following the date of this announcement.
